Lawrence Liberti

991 total citations
43 papers, 587 citations indexed

About

Lawrence Liberti is a scholar working on Economics and Econometrics, Physiology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Lawrence Liberti has authored 43 papers receiving a total of 587 indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Economics and Econometrics, 10 papers in Physiology and 7 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Lawrence Liberti's work include Health Systems, Economic Evaluations, Quality of Life (34 papers), Pharmaceutical Economics and Policy (33 papers) and Biomedical Ethics and Regulation (10 papers). Lawrence Liberti is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (34 papers), Pharmaceutical Economics and Policy (33 papers) and Biomedical Ethics and Regulation (10 papers). Lawrence Liberti collaborates with scholars based in United Kingdom, Netherlands and United States. Lawrence Liberti's co-authors include Neil McAuslane, Stuart Walker, Sam Salek, Ara Der Marderosian, Hubert G. M. Leufkens, Pieter Stolk, Alasdair Breckenridge, Anke M. Hövels, Jarno Hoekman and A Breckenridge and has published in prestigious journals such as Nature Reviews Drug Discovery, PLoS Medicine and Journal of Pharmaceutical Sciences.

In The Last Decade

Lawrence Liberti

42 papers receiving 554 citations

Peers

Countries citing papers authored by Lawrence Liberti

Since Specialization

Citations

This map shows the geographic impact of Lawrence Liberti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lawrence Liberti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lawrence Liberti more than expected).

Fields of papers citing papers by Lawrence Liberti

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lawrence Liberti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lawrence Liberti. The network helps show where Lawrence Liberti may publish in the future.

Co-authorship network of co-authors of Lawrence Liberti

This figure shows the co-authorship network connecting the top 25 collaborators of Lawrence Liberti. A scholar is included among the top collaborators of Lawrence Liberti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lawrence Liberti. Lawrence Liberti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Direct-to-Consumer Genetic Testing: A Comprehensive Review 2023 ·Therapeutic Innovation & Regulatory Science ·(unknown), Lawrence Liberti, (unknown)	8
2	A Mixed Methods Study to Explore Relevant Metrics for a Results Framework Measuring the Public Health Impact of Reliance-Based Pathways 2023 ·Therapeutic Innovation & Regulatory Science ·Inez Adams, Patricia A. Cuff, Lawrence Liberti	0
3	Cooperation Agreements, Memorandums of Understanding, and Letters of Intent as Instruments to Facilitate the Implementation of Reliance in Latin America 2022 ·Clinical Therapeutics ·(unknown), (unknown), Lawrence Liberti	2
4	Transparency in European Medicines Agency and US Food and Drug Administration Decision Making: Is It Possible to Identify the Rationale for Divergences in Approved Indication From Public Assessment Reports? 2021 ·Clinical Therapeutics ·(unknown), (unknown), Neil McAuslane, Lawrence Liberti, Thomas C. Kühler	4
5	An evaluation of the Caribbean regulatory system centralized assessment process for medicines submitted 2017–2018 using the OpERA methodology 2020 ·Journal of Pharmaceutical Policy and Practice ·Lawrence Liberti, (unknown), (unknown), Neil McAuslane	2
6	Use of the Certificate for Pharmaceutical Products (CPP) in 18 Maturing Pharmaceutical Markets: Comparing Agency Guidelines with Company Practice 2020 ·Therapeutic Innovation & Regulatory Science ·(unknown), (unknown), Neil McAuslane, (unknown), Lawrence Liberti	6
7	Benchmarking health technology assessment agencies—methodological challenges and recommendations 2020 ·International Journal of Technology Assessment in Health Care ·(unknown), (unknown), Neil McAuslane, Lawrence Liberti, Anke M. Hövels, Hubert G. M. Leufkens	3
8	Improving access to quality medicines in East Africa: An independent perspective on the East African Community Medicines Regulatory Harmonization initiative 2020 ·PLoS Medicine ·(unknown), Alberto Grignolo, Lawrence Liberti, John C. W. Lim, Tomas Salmonson, (unknown), (unknown)	7
9	To what degree are review outcomes aligned for new active substances (NASs) between the European Medicines Agency and the US Food and Drug Administration? A comparison based on publicly available information for NASs initially approved in the time period 2014 to 2016 2019 ·BMJ Open ·Thomas C. Kühler, (unknown), Neil McAuslane, Lawrence Liberti	8
10	Accelerated approval of medicines: fit for purpose? 2018 ·Nature Reviews Drug Discovery ·Alasdair Breckenridge, Lawrence Liberti	3
11	Building Synergy between Regulatory and HTA Agencies beyond Processes and Procedures—Can We Effectively Align the Evidentiary Requirements? A Survey of Stakeholder Perceptions 2017 ·Value in Health ·(unknown), Neil McAuslane, Lawrence Liberti, Hubert G. M. Leufkens, Anke M. Hövels	34
12	Factors related to drug approvals: predictors of outcome? 2017 ·Drug Discovery Today ·Lawrence Liberti, Alasdair Breckenridge, Jarno Hoekman, Neil McAuslane, Pieter Stolk, Hubert G. M. Leufkens	7
13	FDA Facilitated Regulatory Pathways: Visualizing Their Characteristics, Development, and Authorization Timelines 2017 ·Frontiers in Pharmacology ·Lawrence Liberti, (unknown), Alasdair Breckenridge, Jarno Hoekman, Neil McAuslane, Pieter Stolk, Hubert G.M. Leufkens	23
14	The Benefit-Risk Assessment of Medicines: Experience of a Consortium of Medium-Sized Regulatory Authorities 2017 ·Therapeutic Innovation & Regulatory Science ·Neil McAuslane, (unknown), Lawrence Liberti, Stuart Walker	14
15	An Analysis of Regulatory Timing and Outcomes for New Drug Applications Submitted to Swissmedic: Comparison With the US Food and Drug Administration and the European Medicines Agency 2016 ·Therapeutic Innovation & Regulatory Science ·(unknown), Alison N. Wadworth, Tina Wang, Neil McAuslane, Lawrence Liberti	8
16	Health Technology Assessment (HTA) Case Studies: Factors Influencing Divergent HTA Reimbursement Recommendations in Australia, Canada, England, and Scotland 2016 ·Value in Health ·(unknown), Stuart Walker, Lawrence Liberti, Sam Salek	59
17	Accelerating access to new medicines: Current status of facilitated regulatory pathways used by emerging regulatory authorities 2016 ·Journal of Public Health Policy ·Lawrence Liberti, Alasdair Breckenridge, Jarno Hoekman, Hubert G. M. Leufkens, Murray Lumpkin, Neil McAuslane, Pieter Stolk, Kaining Zhi, Lembit Rägo	18
18	Do HTA Processes Correlate With Reimbursement Recommendations? 2014 ·Value in Health ·(unknown), (unknown), Lawrence Liberti, Sam Salek	2
19	Characterizing Good Review Practices: A Survey Report Among Agencies of APEC Member Economies 2013 ·Therapeutic Innovation & Regulatory Science ·(unknown), Neil McAuslane, (unknown), Herng‐Der Chern, Lawrence Liberti, Mike Ward, Jaw‐Jou Kang	9
20	—CMR International Institute for Regulatory Science Workshop on Measuring Benefit and Balancing Risk 19–20 June 2008 Washington, DC 2009 ·Clinical Pharmacology & Therapeutics ·Stuart Walker, Neil McAuslane, Lawrence Liberti, Sam Salek	23

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact